XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.1
BUSINESS ACQUISITIONS - Pharmaceutical Technologies, Inc. (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 27, 2017
Nov. 24, 2017
Dec. 31, 2018
Dec. 31, 2017
May 08, 2017
Dec. 31, 2016
Dec. 31, 2014
Summary of the preliminary fair value determination of the acquired assets and liabilities              
Definite-lived intangible assets         $ 7,730    
Goodwill     $ 609,592 $ 832,624   $ 316,616 $ 256,318
Pharmaceutical Technologies, Inc.              
BUSINESS ACQUISITIONS              
Cash $ 36,534            
Restricted common shares 12,753            
Total $ 49,287            
Restricted common shares (in shares) 835,017            
Market price (in dollars per share)   $ 16.97          
Market price multiplier to factor in restricted nature of the shares (as a percent)   90.00%          
Purchase consideration deposited into an escrow account $ 9,005            
Acquisition-related costs charged to Selling, general, and administrative expenses     $ 555 $ 804      
Summary of the preliminary fair value determination of the acquired assets and liabilities              
Cash 9,851            
Accounts receivable 20,622            
Inventories 200            
Prepaid expenses and other current assets 650            
Property and equipment 13,544            
Capitalized software for internal use 1,800            
Definite-lived intangible assets 6,720            
Accounts payable (14,968)            
Rebates payable (7,882)            
Accrued expenses - compensation and benefits (160)            
Accrued expenses - other (4,891)            
Total identifiable net assets 25,486            
Goodwill 23,801            
Total acquisition price $ 49,287            
Pharmaceutical Technologies, Inc. | Minimum              
BUSINESS ACQUISITIONS              
Deposit term into an escrow account 18 months            
Pharmaceutical Technologies, Inc. | Maximum              
BUSINESS ACQUISITIONS              
Deposit term into an escrow account 36 months            
Customer relationships | Pharmaceutical Technologies, Inc.              
Summary of the preliminary fair value determination of the acquired assets and liabilities              
Definite-lived intangible assets $ 5,900            
Definite-lived intangible assets              
Useful Life 10 years            
Trade names and trademarks | Pharmaceutical Technologies, Inc.              
Summary of the preliminary fair value determination of the acquired assets and liabilities              
Definite-lived intangible assets $ 820            
Definite-lived intangible assets              
Useful Life 2 years